Kandrotas R J, Oles K S, Gal P, Love J M
Moses H. Cone Memorial Hospital, Greensboro, N.C.
DICP. 1989 Feb;23(2):137-40. doi: 10.1177/106002808902300206.
A 47-year-old woman with endstage renal disease and dialysis-induced encephalopathy was being treated with carbamazepine for myoclonus. Her carbamazepine serum concentration appeared to be therapeutic at 5.1 micrograms/ml. She experienced a seizure while on hemodialysis/hemoperfusion that was possibly related to the removal of carbamazepine during dialysis. The elimination of carbamazepine on a dialysis day was compared with elimination on a nondialysis day. The half-life and apparent clearance were the same for each day, indicating that hemodialysis/hemoperfusion had little effect on the overall removal of carbamazepine from the body. The possible reasons for this lack of effect are discussed.
一名患有终末期肾病和透析性脑病的47岁女性正在接受卡马西平治疗肌阵挛。她的卡马西平血清浓度为5.1微克/毫升,似乎处于治疗水平。她在血液透析/血液灌流期间发生了一次癫痫发作,这可能与透析过程中卡马西平的清除有关。将透析日卡马西平的清除情况与非透析日进行了比较。每天的半衰期和表观清除率相同,表明血液透析/血液灌流对卡马西平从体内的总体清除影响很小。文中讨论了这种无效的可能原因。